# A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

> **NCT05919082** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 604 (actual)

## Conditions studied

- Stable Plaque Psoriasis

## Interventions

- **DRUG:** LEO 90100
- **DRUG:** Daivobet® ointment

## Key facts

- **NCT ID:** NCT05919082
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-21
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-03-05
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919082, "A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05919082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*